Friday, 11 September 2015
AstraZeneca today added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc. Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.
AstraZeneca plans to start staffing the facility immediately to support refurbishment and infrastructure improvements. Once complete, the site is expected to be operational and licensed for commercial production by late 2017, providing for additional capacity within the company’s biologics operations.
In the longer- term, this site could create up to 400 highly skilled jobs, subject to relevant approvals by the local authorities. The facility will eventually double the biologics manufacturing capacity in the US to meet the needs of the maturing AstraZeneca pipeline. Currently biologics make up 50 percent of the company’s pipeline with more than 120 ongoing programmes, including over 30 in clinical development.
Pam Cheng, Executive Vice-President, Operations and Information Technology at AstraZeneca, said: “The addition of the Boulder facility will support the progression of biotech drug candidates across our main therapeutic areas as we continue to bring innovative new treatments to patients. This site will play an important role in our future commercial production and give AstraZeneca and MedImmune, our global biologics research and development arm, the flexibility and capacity to meet the needs of our rapidly growing biologics portfolio.”
The new facility in Boulder adds to the expansion of AstraZeneca’s biologics manufacturing capabilities, following the planned biologics manufacturing investment in Sweden, announced in May, and the expansion in Frederick, Maryland, announced in November 2014.
The financial details were not disclosed. This investment does not impact AstraZeneca’s financial guidance for 2015.
NOTES FOR EDITORS
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
| Media Enquiries | ||
|---|---|---|
| Esra Erkal-Paler | (UK/Global) | +44 20 7604 8030 |
| Vanessa Rhodes | (UK/Global) | +44 20 7604 8037 |
| Ayesha Bharmal | (UK/Global) | +44 20 7604 8034 |
| Karen Birmingham | (UK/Global) | +44 20 7604 8120 |
| Jacob Lund | (Sweden) | +46 8 553 260 20 |
| Michele Meixell | (US) |
+1 302 885 6351 |
| Investor Enquiries UK | ||
|---|---|---|
| Thomas Kudsk Larsen | +44 20 7604 8199 | mob: +44 781 852 4185 |
| Eugenia Litz (Respiratory,Inflammation and Autoimmunity) |
+44 20 7604 8233 | mob: +44 788 473 5627 |
| Nick Stone (Cardiovascular and Metabolic Disease) |
+44 17 6326 3994 | mob: +44 771 761 8834 |
Karl Hård |
+44 20 7604 8123 | mob: +44 778 965 4364 |
| Craig Marks (Infection,Neuroscience and Gastrointestinal Disease) |
+44 20 7604 8591 | mob: +44 788 161 5764 |
| Christer Gruvris | +44 20 7604 8126 | mob: +44 782 783 6825 |
| Investor Enquiries US | ||
|---|---|---|
| Lindsey Trickett | +1 301 398 5118 | mob: +1 301 398 3251 |
| Dial / Toll-Free | +1 301 398 3251 | mob: +1 866 381 7277 |